フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
RALEIGH, N.C. and WELLESLEY HILLS, Mass., Feb. 12 /PRNewswire/ -- DARA BioSciences, Inc. ("DARA") and Point Therapeutics, Inc. ("Point...
CUSIP No. 232674507 13G Page 1 of 19 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE...
Point Therapeutics, Inc. (NASDAQ: POTP) today announced that it has received proxies sufficient to approve the pending merger...
Filed by Point Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended and...
RALEIGH, N.C., Feb. 4 /PRNewswire/ -- DARA BioSciences, Inc. today announced that the Company will present at the ROTH 20th Annual Growth Stock...
Point Therapeutics, Inc. (NASDAQ: POTP) today announced that it has adjourned its annual meeting of stockholders, which...
Point Therapeutics, Inc. (NASDAQ: POTP) announced today that, as anticipated, Point received an additional notice of...
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT...
Point Therapeutics, Inc. (NASDAQ: POTP) today announced that the Securities and Exchange Commission has declared effective its...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
サインアップして広告なしのエクスペリエンスを体験してください
今すぐ試してください
広告を残す